Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

NEWS

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.

PUBLISHED

26 January 2023

RECENT POSTS

Khaliun Gan-Erdene, MD, Awarded the 2025 Siriraj International Fellowship in Clinical Pain Management

21 March 2025

Position Statement: IASP Reaffirms Commitment to Diversity, Equity, and Inclusion

14 March 2025

IASP Appoints Rikard Wicksell, PhD, as New WHO Liaison

14 February 2025

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain 

03 February 2025

Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.

Posted in
Share this